However, women with advanced non-small cell lung cancer (NSCLC) experienced an impressive, more considerable survival benefit than men from the combination of chemotherapy with an anti-PD-1 or anti-PD-L1 [26]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.